Reaction
Bone Marrow Infiltration reporting signals
As of the last recalculation, Bone Marrow Infiltration appears in 381 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is RIBOCICLIB (PRR 79.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ribociclib | 41 | 79.4 | 79.5 |
| Fulvestrant | 32 | 57.7 | 57.7 |
| Goserelin | 13 | 54.7 | 54.8 |
| Polatuzumab Vedotin | 9 | 51.6 | 51.6 |
| Pertuzumab | 24 | 51.4 | 51.4 |
| Exemestane | 19 | 50.9 | 51.0 |
| Letrozole Tablets | 38 | 47.8 | 47.9 |
| Bendamustine Hcl | 13 | 47.4 | 47.4 |
| Cyclobenzaprine Hydrochloride | 7 | 43.3 | 43.4 |
| Bendamustine Hydrochloride | 9 | 42.0 | 42.1 |
| Ado-Trastuzumab Emtansine | 6 | 39.5 | 39.5 |
| Letrozole | 38 | 37.3 | 37.4 |
| Zoledronic Acid | 24 | 34.8 | 34.8 |
| Abemaciclib | 12 | 33.8 | 33.9 |
| Pegaspargase | 7 | 31.8 | 31.8 |
| Carfilzomib | 13 | 26.0 | 26.0 |
| Docetaxel Anhydrous | 29 | 25.4 | 25.4 |
| Docetaxel | 29 | 25.4 | 25.4 |
| Gemcitabine | 16 | 23.1 | 23.1 |
| Lapatinib | 6 | 21.4 | 21.5 |
| Gemcitabine Hydrochloride | 19 | 20.5 | 20.5 |
| Abiraterone | 4 | 16.2 | 16.2 |
| Ixazomib | 7 | 13.5 | 13.5 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 3 | 12.5 | 12.5 |